Smoldering myeloma
FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
FDA approval; Darzalex Faspro; high-risk smoldering multiple myeloma; AQUILA study; early intervention; progression-free survival; daratumumab; hyaluronidase-fihj